The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA's Overreach on Compounded Peptides Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law BPC 157 And TB 500: Background, Indications, Efficacy, And Safety GlobalRPH